{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:54:27Z","timestamp":1767117267827,"version":"3.37.3"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010876","name":"Vasculitis UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010876","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Versus Arthritis Clinical Research"},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["22727"],"award-info":[{"award-number":["22727"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","award":["NIHR300863"],"award-info":[{"award-number":["NIHR300863"]}],"id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/T017619\/1"],"award-info":[{"award-number":["BB\/T017619\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHS"},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses. We conducted an observational study to evaluate the short-term humoral and cell-mediated T cell response after the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in RAIRD patients compared with healthy controls (HCs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Blood samples were collected after the second dose and anti-spike, anti-nucleocapsid antibody levels and SARS-CoV-2-specific T cell responses were measured and compared with those of HCs. Activation-induced marker and deep phenotyping assays were used to identify differences in T cells between high and no\/low antibody groups, followed by multidimensional clustering.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 50 patients with RAIRDs were included (31 with AAV, 4 with other systemic vasculitis, 9 with SLE and 6 with myositis). The median anti-spike levels were significantly lower in RAIRD patients compared with HCs (P\u2009&amp;lt;\u20090.0001). Fifteen (33%) patients had undetectable levels and 26 (57%) had levels lower than the lowest HC. Rituximab in the last 12\u2009months (P\u2009=\u20090.003) was associated with reduced immunogenicity compared with a longer pre-vaccination period. There was a significant difference in B cell percentages (P\u2009=\u20090.03) and spike-specific CD4+ T cells (P\u2009=\u20090.02) between no\/low antibody vs high antibody groups. Patients in the no\/low antibody group had a higher percentage of terminally differentiated (exhausted) T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Following two doses, most RAIRD patients have lower antibody levels than the lowest HC and lower anti-spike T cells. RAIRD patients with no\/low antibodies have diminished numbers and poor quality of memory T cells that lack proliferative and functional capacities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac574","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T12:52:16Z","timestamp":1665751936000},"page":"2294-2303","source":"Crossref","is-referenced-by-count":7,"title":["Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-1207","authenticated-orcid":false,"given":"Leher","family":"Gumber","sequence":"first","affiliation":[{"name":"Nottingham University Hospitals NHS Trust , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Gomez","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Hopkins","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davis","family":"Tucis","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bartlett","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-8800","authenticated-orcid":false,"given":"Kieran","family":"Ayling","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Vedhara","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Steers","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithun","family":"Chakravorty","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Rutter","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust , Nottingham, UK"},{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Jackson","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Tighe","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nottingham University Hospitals NHS Trust , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Power","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jos\u00e8phe","family":"Prad\u00e8re","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Onion","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C","family":"Lanyon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust , Nottingham, UK"},{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-1998","authenticated-orcid":false,"given":"Fiona A","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust , Nottingham, UK"},{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Fairclough","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham , Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2023060113245613300_keac574-B1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2023060113245613300_keac574-B2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060113245613300_keac574-B3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/rheumatology\/keaa855","article-title":"Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic","volume":"60","author":"Peach","year":"2021","journal-title":"Rheumatology"},{"key":"2023060113245613300_keac574-B6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2020-217984","article-title":"Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Freites Nu\u00f1ez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B8","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2665-9913(21)00247-2","article-title":"COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses","volume":"3","author":"Fagni","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023060113245613300_keac574-B9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2021-220549","article-title":"B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics","volume":"81","author":"Felten","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B11","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/S2665-9913(20)30270-8","article-title":"B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2023060113245613300_keac574-B12","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2020-218075","article-title":"Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab","volume":"80","author":"Schulze-Koops","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2021-150220","article-title":"Vaccine efficacy after rituximab exposure: first interim analysis of virtue project on behalf of West Midlands Research Consortium, UK","volume":"138","author":"Shields","year":"2021","journal-title":"Blood"},{"key":"2023060113245613300_keac574-B14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B15","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023060113245613300_keac574-B16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.42060","article-title":"B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab","volume":"74","author":"Stefanski","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113245613300_keac574-B17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.41914","article-title":"Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113245613300_keac574-B19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B20","doi-asserted-by":"crossref","first-page":"846248","DOI":"10.3389\/fimmu.2022.846248","article-title":"Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study","volume":"13","author":"Szebeni","year":"2022","journal-title":"Front Immunol"},{"key":"2023060113245613300_keac574-B21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-12-814649-1.00004-1","volume-title":"In: Human microbiota in health and disease: From pathogenesis to therapy","author":"Tungland","year":"2018"},{"year":"2022","author":"Vedhara","key":"2023060113245613300_keac574-B22"},{"key":"2023060113245613300_keac574-B23","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2023060113245613300_keac574-B24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023060113245613300_keac574-B25","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1016\/j.vaccine.2013.05.004","article-title":"Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: immunogenicity and safety?","volume":"31","author":"Y\u0131ld\u0131z","year":"2013","journal-title":"Vaccine"},{"key":"2023060113245613300_keac574-B26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-015-0663-9","article-title":"Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases \u2013 a longitudinal study","volume":"17","author":"Fischer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023060113245613300_keac574-B27","doi-asserted-by":"crossref","first-page":"744206","DOI":"10.3389\/fimmu.2021.744206","article-title":"Effects of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"2023060113245613300_keac574-B28","doi-asserted-by":"crossref","first-page":"e338\u201350","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023060113245613300_keac574-B29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023060113245613300_keac574-B30","doi-asserted-by":"crossref","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"2023060113245613300_keac574-B31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023060113245613300_keac574-B32","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3910058","article-title":"Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity \u2013 the OCTAVE Trial","author":"Kearns","year":"2021","journal-title":"SSRN Electron J Published Online First"},{"key":"2023060113245613300_keac574-B33","doi-asserted-by":"crossref","first-page":"e177\u201387","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023060113245613300_keac574-B34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: b cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"&gt;Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023060113245613300_keac574-B35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.42058","article-title":"Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases","volume":"74","author":"Bitoun","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113245613300_keac574-B36","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2023060113245613300_keac574-B37","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1038\/s41467-021-25167-5","article-title":"Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern","volume":"12","author":"Skelly","year":"2021","journal-title":"Nat Commun"},{"key":"2023060113245613300_keac574-B38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"2023060113245613300_keac574-B39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.kint.2021.03.014","article-title":"Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients","volume":"99","author":"Benotmane","year":"2021","journal-title":"Kidney Int"},{"key":"2023060113245613300_keac574-B40","doi-asserted-by":"crossref","first-page":"e94\u20135","DOI":"10.1097\/TP.0000000000003784","article-title":"Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept","volume":"105","author":"Chavarot","year":"2021","journal-title":"Transplantation"},{"key":"2023060113245613300_keac574-B41","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2021070966","article-title":"B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients","volume":"32","author":"Schrezenmeier","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2023060113245613300_keac574-B42","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.4049\/jimmunol.178.7.4112","article-title":"Four functionally distinct populations of human effector-memory CD8+ T lymphocytes","volume":"178","author":"Romero","year":"2007","journal-title":"J Immunol"},{"key":"2023060113245613300_keac574-B43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cyto.b.20610","article-title":"Altered T cell differentiation associated with loss of CD27 and CD28 in HIV infected Indian individuals","volume":"82","author":"Mojumdar","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"year":"2021","author":"Department of Health and Social Care","key":"2023060113245613300_keac574-B44"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac574\/46908473\/keac574.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2294\/50500866\/keac574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2294\/50500866\/keac574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:36:57Z","timestamp":1685626617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/6\/2294\/6762096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac574","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,10,17]]}}}